Serelaxin hits roadblock in Europe

The Committee for Medicinal Products for Human Use (CHMP) recommended that serelaxin not be approved as a treatment to relieve symptoms in patients with acute heart failure. The European committee’s decision could influence an FDA panel that will review the drug’s application in February.

Serelaxin is a vasoactive peptide hormone that helps to relax the blood vessels and reduce fluid buildup. In the international placebo-controlled randomized RELAX-AHF trial, serelaxin was found to provide dyspnea relief in patients with acute heart failure who had been admitted to a hospital but treatment had no effect on hospital readmission.

In its opinion, CHMP highlighted results that showed serelaxin failed to provide short-term relief but that it did show benefits over five days. The committee questioned the clinical relevance of that benefit and called for further studies.

In a release, Novaris said it planned to submit a revised filing with new analyses. The company has a 15-day window after notification to request a re-examination of the CHMP’s decision.

The FDA’s Cardiovascular and Renal Drugs Advisory Committee is scheduled to discuss serelaxin at its Feb. 13 meeting.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup